InspireMD Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

NSPR$0.71+2.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Equity

Common stock · Series C Convertible Preferred Stock · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT January 1, 2023	8,330,918	1	1,718	- *	218,977	(201,585)	17,393
Net loss						(14,511)	(14,511)
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs	10,266,270	1	-	-	37,533		37,534
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 14,019 shares	2,802,975	-*	-	-	2,841		2,841
BALANCE AT September 30, 2023	21,400,163	2	1,718	- *	259,351	(216,096)	43,257

*	Represents an amount less than $1 thousand

Common stock · Series C Convertible Preferred Stock · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT July 1, 2023	21,192,204	2	1,718	-*	257,729	(210,918)	46,813
Net loss						(5,178)	(5,178)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 9,749 shares	207,959	-*	-	-	1,622		1,622
BALANCE AT September 30, 2023	21,400,163	2	1,718	- *	259,351	(216,096)	43,257

*	Represents an amount less than $1 thousand

Common stock · Series C Convertible Preferred Stock · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT January 1, 2024	21,841,215	2	1,718	- *	261,000	(221,501)	39,501
Net loss						(22,831)	(22,831)
Exercise of pre-funded warrants	1,728,382	- *		-			-*
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of $1,000 issuance costs	292,996	1		-	16,853		16,854
Issuance of common shares, Included at the market offering net of $1 issuance costs	12,961			-	35		35
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 112,382 shares	1,844,078	- *		-	7,792		7,792
BALANCE AT September 30, 2024	25,719,632	3	1,718	-*	285,680	(244,332)	41,351

*	Represents an amount less than $1 thousand

Common stock · Series C Convertible Preferred Stock · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT July 1, 2024	25,196,479	3	1,718	-*	283,202	(236,442)	46,763
Net loss						(7,890)	(7,890)
Exercise of pre-funded warrants	199,992	- *	-	-	-		- *
Issuance of common shares, Included at the market offering net of $1 issuance costs	12,961				35		35
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award	310,200				2,443		2,443
BALANCE AT September 30, 2024	25,719,632	3	1,718	- *	285,680	(244,332)	41,351

*	Represents an amount less than $1 thousand

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.